http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novavax (NVAX) Confirms EMA is Reviewing COVID-19 Vaccine Filing for Conditional Marketing Authorization
-
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization
-
Novavax (NVAX) And Serum Institute of India Granted Emergency Use Authorization for COVID-19 Vaccine in the Philippines
-
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
-
Novavax (NVAX) Submits Biologics License Application in South Korea for Approval of NVX-CoV2373
-
Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373
-
Novavax (NVAX) Files for WHO Emergency Use Listing of its COVID-19 Vaccine
-
Novavax Reports Third Quarter 2021 Financial Results and Operational Highlights
-
Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization
-
Novavax (NVAX) Files for Provisional Approval of its COVID-19 Vaccine in New Zealand
-
Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand
-
Novavax (NVAX) and Serum Institute of India Granted Emergency Use Authorization for Novavax' COVID-19 Vaccine in Indonesia
-
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
-
Novavax (NVAX) Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to EMA
-
Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency
-
Novavax (NVAX) Files Requesting Provisional Approval of its COVID-19 Vaccine in Australia
-
Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia
-
Novavax (NVAX) Files For UK Authorization of its COVID-19 Vaccine
-
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
-
Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
-
Novavax (NVAX) Will Participate in World Vaccine Congress Europe
-
Novavax to Participate in World Vaccine Congress Europe
-
Novavax (NVAX) Announces Leadership Appointment and Updates
-
Novavax Announces Leadership Appointment and Updates
-
Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
-
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
-
Novavax's (NVAX) NanoFlu Influenza Vaccine Phase 3 Results Published in The Lancet ID; Vaccine Produced Significant Enhanced Humoral and Cellular Responses
-
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
-
Novavax (NVAX) and Serum Institute of India Apply to WHO for Emergency Use Listing of Novavax' COVID-19 Vaccine
-
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
-
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
-
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
-
Novavax (NVAX) to Compare Mixed COVID-19 Vaccine Schedules in Adolescents in a New Phase 2 Study With University of Oxford
-
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
-
Novavax to Participate in Upcoming September Conferences
-
Novavax (NVAX) Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
-
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
-
Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
-
Novavax's (NVAX) Trial Patients Considered Fully Vaxxed Per CDC Guidelines; Company Releases Statement
-
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
-
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
-
Novavax (NVAX) Appoints Jim Kelly as CFO
-
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
-
Novavax (NVAX) and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Va
-
Novavax (NVAX) Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
-
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights
-
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
-
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
-
Novavax (NVAX), European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
-
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
